Executive Summary: 2021 Strategic Plan
ICAN, International Cancer Advocacy Network

The organization recognizes three categories to pursue over the next 5 years. For 25 years, ICAN has not expanded without funds in hand, nor will its leadership begin to do so. The Board is fully cognizant that the goals delineated are dependent upon the course of the pandemic, the condition of the economy, and the sustaining of the organization’s acclaimed patient services.

1) Patient Program Services

Goal: Continue world class advocacy for pan-heme, pan-tumor, pan-rare cancer patients and their families in the U.S. and in 54 countries, providing direct patient navigation, molecular profiling matching services, clinical trials matching services, expanded access matching services, while also prioritizing health equity issues and health information technology issues
Funding: Grateful patients and their families, philanthropists, foundations, corporations, and special events
Challenges to overcome: Funding decline in the event of a continuing pandemic.
Additional staffing hires: CMO, CSO

2) Precision Medicine Public Policy Advocacy Programs

Goal: Continue prodigious efforts, collaborations, and initiatives working in the overwhelming majority of state legislatures on 8 to 10 issues of continuing interest to the U.S. cancer community; continue education of Members of Congress, legislative health policy staff, and Agency staff
Funding: Specific public policy grants
Challenges to overcome: Continued understaffing given the huge demand for our involvement
Additional staffing hires: Analysts and Legislative Assistants

3) Exon 20 Group

Goal: Transform exon 20 diagnoses into chronic, manageable diseases with the highest attainable quality of life. Continue transformative services for hundreds of EGFR exon 20 insertion and HER2 exon 20 insertion patients and their care partners and family members (each mutation having a reach of 24 separate cancers in addition to Non-Small Cell Lung Cancer); continue to build the multi-stakeholder wings of the Exon 20 Group, including Thoracic and Medical Oncologists; Molecular Profiling Laboratories and molecular pathologists; industry partners with exon 20 drugs in the pipeline; cancer biologists and medicinal chemists; continue to fund top laboratories on resistance mutations and immune cell studies.
Funding: Grateful patients and their families (funding has been mostly spontaneous since 2017) as well as philanthropists, foundations, corporations, and special events
Challenges to overcome: Improve and accelerate the identification of more patients to be able to serve more patients at the outset of their diagnosis or diagnosis of metastasis
Additional staffing hires: VP, Scientific Affairs; Nursing Staff

Board Book signature on file
Board Governance Document 018, Board Book